683 Capital Management, LLC Sqz Biotechnologies CO Transaction History

683 Capital Management, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$0.67 - $2.85 $612,454 - $2.61 Million	-914,111 Reduced 40.72%	1,330,889 $984,000
Q3 2022 Nov 14, 2022	BUY	$2.16 - $3.48 $188,485 - $303,671	87,262 Added 4.04%	2,245,000 $5.12 Million
Q2 2022 Aug 15, 2022	BUY	$2.77 - $5.0 $163,216 - $294,615	58,923 Added 2.81%	2,157,738 $6.86 Million
Q1 2022 May 16, 2022	BUY	$4.01 - $10.42 $989,186 - $2.57 Million	246,680 Added 13.32%	2,098,815 $10.1 Million
Q4 2021 Feb 14, 2022	BUY	$8.93 - $14.85 $1.43 Million - $2.37 Million	159,748 Added 9.44%	1,852,135 $16.5 Million
Q3 2021 Nov 15, 2021	BUY	$11.46 - $15.77 $3.64 Million - $5 Million	317,216 Added 23.07%	1,692,387 $24.4 Million
Q2 2021 Aug 16, 2021	BUY	$11.32 - $14.45 $8.91 Million - $11.4 Million	787,193 Added 133.88%	1,375,171 $19.9 Million
Q1 2021 May 17, 2021	BUY	$12.07 - $29.9 $1.47 Million - $3.64 Million	121,802 Added 26.13%	587,978 $8.04 Million
Q4 2020 Feb 16, 2021	BUY	$13.25 - $34.58 $6.18 Million - $16.1 Million	466,176 New	466,176 $13.5 Million

1.47M

Ticker SQZ
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 29,248,600
Market Cap $1.46M
Description
SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination ...

Get notified when there are updates to the investment portfolio of 683 Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on 683 Capital Management, LLC with notifications on news.